Biogen, Inc.
14 Cambridge Center
Cambridge
Massachusetts
02142
United States
Tel: 617-679-2000
62 articles about Biogen, Inc.
-
FDA Approves Biogen, Inc.'s Hemophilia A Drug Eloctate
6/9/2014
-
Biogen, Inc. Profit Rises As New Multiple Sclerosis Drug Shines
1/29/2014
-
Social Media Suggests an MS Dogfight Between Biogen, Inc. and Novartis AG
5/24/2013
-
Biogen, Inc. Release: FAMPYRA(TM), the First Oral Treatment for the Improvement of Walking in MS, is Now Available in Canada
4/11/2012
-
Biogen, Inc. Takes Option to MAKScientific, LLC MS Program
3/15/2012
-
Biogen, Inc. Appoints Kenneth DiPietro Executive Vice President, Human Resources
1/30/2012
-
Biogen, Inc., and Elan Corporation PLC Release: ASCEND Study to Evaluate the Effectiveness of TYSABRI® (natalizumab) as a Treatment for Secondary-Progressive Multiple Sclerosis
1/26/2012
-
Biogen, Inc. to Report Fourth Quarter & Year End 2011 Financial Results on January 31, 2012
1/17/2012
-
Biogen, Inc. to Present at the Goldman, Sachs & Co. Healthcare CEOs Unscripted Conference
12/29/2011
-
Biogen, Inc. Reports Third Quarter 2011 Results
10/28/2011
-
Biogen, Inc. to Close Sites, Cut 650 Jobs
11/4/2010
-
Biogen, Inc. to Implement Restructuring Program; to Cut Jobs
10/27/2010
-
Biogen, Inc. Buys License to Late-Stage Nerve Disease Pill From Knopp NeuroSciences for $345 Million
8/18/2010
-
Facet Biotech Board Rejects Biogen, Inc. Bid
10/1/2009
-
Biogen, Inc. Downplays Virus Threat with MS Drug Tysabri
9/11/2009
-
US Judge Finds Biogen, Inc. Breached Pact with Biogen (JOBS)
9/4/2009
-
Elan Corporation PLC Sues as Biogen, Inc. (JOBS) Seeks Control Over Tysabri
8/7/2009
-
Icahn Accuses Biogen, Inc. of Attempting to Hijack Vote
6/3/2009
-
Michael Lytton Leaves Oxford Bioscience Partners for Biogen, Inc.
2/26/2009
-
Biogen, Inc. to Present at the Lazard Capital Markets Fifth Annual Life Sciences Conference
11/14/2008